The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
As set out above, certification has already become a feature of international travel, with the UK and many other countries requiring evidence of a negative test pre-departure as part of their border regimes. The Government expects such requirements to continue and is exploring ways of making certification of testing MORE DIGITAL AND INTEGRATED - as well as considering the implications of vaccines and what certification may be required around them.
The requirements around international travel are necessarily high. In addition, the Government is considering what standards should be required for COVID-status certification for domestic settings. The Government expects that COVID-status certification could be demonstrated by: an up-to-date vaccine status; a negative lateral flow or PCR test taken at a test site on the same day or the day before their admission to a venue; or by proof of natural immunity, such as through a previous positive PCR for a time limit of 180 days from the date of the positive test and following completion of the self-isolation period. We will test approaches to COVID-status certification through the Events Research Programme.
https://www.gov.uk/government/publications/covid-19-response-spring-2021-reviews-terms-of-reference/roadmap-reviews-update
i - P R O T E C T
Cough?
https://www.sharecast.com/equity/Braveheart_Investment_Group/director-deals
Lead author Jon Deeks, professor of biostatistics at the University of Birmingham, said: "These tests work a lot less well in people who are asymptomatic than symptomatic. The government has not been clear on this.
"The only data we have is based on the [Liverpool and Birmingham] studies, where a total of 78 people had COVID-19, when 40 million tests have been given out.
"I personally find it quite shocking that the government thinks this is an adequate evidence base on which to base such a large, expensive, and quite invasive policy."
https://www.google.co.uk/amp/s/news.sky.com/story/amp/covid-19-how-do-lateral-flow-tests-work-and-how-will-englands-twice-weekly-programme-take-place-12266517
Sounds like another wave and lockdown is inevitable.
Delivering mass testing on the scale and level of ambition set by the UK prime minister, Boris Johnson, will probably require “testing technology that currently does not exist,” say leaked documents revealed by The BMJ.1
The Operation Moonshot plans, which could see the government spend over £100bn to ensure 10 million covid-19 tests a day, show it’s likely that new testing technology would need to be developed, validated, procured, and made operational within months to meet the early 2021 deadline.
Jon Deeks, professor of biostatistics at the University of Birmingham and leader of the Cochrane Collaboration’s covid-19 test evaluation activities, has described the plan as a “nice dream.”
He told The BMJ, “This is not the way we should be tackling something when people are dying right now: thinking about things we have not got. We should be thinking about the things we have got and we know work. Backing a horse that hasn’t yet been born is a really bad strategy.”
https://www.bmj.com/content/370/bmj.m3585
Guess what... the government will need to ensure this tech capable of carrying out 10m tests a day every day no longer remains a dream. Paraytec’s device can turn that dream into reality.
It is about SCALE, it is about SPEED, it is about COST, it is about ACCURACY, it is about USABILITY and also about FLEXIBILITY regarding new strains/pathogens.
Your golden standard dream stock will come second in SPEED, SCALE, ACCURACY, USABILITY (0.1ml) and COST.
Andy, you ask some very sensible questions IMO.
‘Our CEO has just unloaded 6% onto the market, some at a price lower than present SP, which indicates that he sees that as good value, whilst we may not agree, he is in a better position of clarity than us.’
Trevor buys and sells within Braveheart all the time and IMO it is impossible to gauge anything from it.
Looking back to 3rd June 2020 RNS Trevor sold 3,092,057 shares at 22.19p leaving 4,983,877 Ordinary Shares, equivalent to approximately 15.89 per cent.
Following the latest RNS he is still holding 5,424,099 shares at a far, far, far greater value (300%+) than 10 months ago. (Nice if you can get it!)
I respectfully disagree with the ‘good value’ comment. He certainly juggles a percentage in and out for reasons only known to himself but a core Braveheart holding worth far more in a short period remains in place.
Nature waits for no one with or without a passport.
India's battle with the double mutant coronavirus mutation
India is also combating the onset of the 'double mutant' variant which was recently discovered in the country.
A double mutant variant refers to the merging of two mutations of a virus strain that go on to form a third, super infectious strain. The first case of double mutation in India was discovered in the state of Maharashtra.
With the help of genome sequencing and sample testing, scientists have been able to detect a sharp rise in the E484Q and L452R mutations since December. It is believed that the double mutant variants have the ability to surpass the immune system and be highly resistant to antibodies.
https://www.google.co.uk/amp/s/m.timesofindia.com/v/s/m.timesofindia.com/life-style/health-fitness/health-news/coronavirus-vaccine-how-effective-are-covid-vaccines-against-the-new-variants-heres-what-experts-suggest/amp_etphotostory/81833138.cms%3famp_js_v=0.1&usqp=mq331AQHKAFQArABIA%253D%253D#ampf=
We only need 1% 2% 3% 4% of the global market. Our market cap is so low and our product is simply so good. There is absolutely no reason why we cannot achieve that small share of the Covid testing market.
Of course, this is only for Covid but we know it will expand way beyond this into other areas.